ACR 0.00% 5.6¢ acrux limited

Not good figures, page-36

  1. 7,159 Posts.
    lightbulb Created with Sketch. 546
    it is not a stupidity.
    $4 years ago, market was pricing Axiron as a big potential for further revenue increase.
    At $0.72, market today is worried next quarter sales will be further reduced.

    I think some explanation or interpretation of Q2 figure from ACR (or Lilly) will help to clarify, unfortunately ACR got its mouth firmly shut, that's the worry!

    Abbvie had a improved quarter for Androgel, means the market revenue/volume was not deeply impacted. ACr need to tell us why the Q2 is bad for Axiron.
 
watchlist Created with Sketch. Add ACR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.